Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: A clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies. The company modifies existing FDA-approved oncology drugs to improve safety and efficacy profiles. Key pipeline assets include NGC-Cap (Phase 2), NGC-Gem, and NGC-Iri. The company has no product revenue and relies on equity financing.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,834,405) | $(2,726,381) |
| Net Loss Per Share (Basic & Diluted) | $(0.30) | $(1.11) |
| Operating Expenses | $2,846,990 | $2,809,598 |
| Cash and Cash Equivalents (End of Period) | $2,897,072 | $8,920,363 |
| Net Cash Used in Operating Activities | $(2,729,848) | $(2,048,884) |
| Net Cash Provided by Financing Activities | $4,435,595 | $6,263,050 |
| Total Assets | $4,809,574 | $3,229,289 |
| Accumulated Deficit | $(90,053,604) | $(78,095,462) |
Material Changes vs. Prior Period
- Financing Activity: In January 2025, the company completed a public offering raising net proceeds of approximately $4.4 million through the sale of common stock, pre-funded warrants, and Series A/B warrants. This contrasts with $6.3 million raised in Q1 2024.
- Liquidity Position: Cash balances increased from $1.19 million at year-end 2024 to $2.90 million at March 31, 2025, driven by the Q1 financing. However, cash balances are significantly lower than the $8.92 million reported in Q1 2024.
- Operating Expenses: Total operating expenses increased slightly by $37,392 year-over-year. Research and Development (R&D) expenses rose by $49,470 due to increased clinical trial costs for NGC-Cap, partially offset by a $12,078 decrease in General and Administrative (G&A) expenses.
- Share Count: Weighted average shares outstanding increased significantly to 9.53 million in Q1 2025 from 2.47 million in Q1 2024, largely due to the inclusion of pre-funded warrants in the EPS calculation, resulting in a lower loss per share despite a higher total net loss.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current cash resources ($2.9 million) are sufficient to fund operations only into mid-2025. The filing explicitly states that "substantial doubt exists" about the company's ability to continue as a going concern within one year without additional financing.
- Capital Needs: The company plans to raise additional funds via equity offerings, debt, or strategic alliances. Failure to secure funding could force delays or suspension of clinical trials.
- Nasdaq Compliance: The company received a deficiency letter on February 4, 2025, regarding non-compliance with the $1.00 minimum bid price requirement. It has 180 days (until August 4, 2025) to regain compliance or face potential delisting.
- Legal Proceedings:
- Elion Oncology: A dispute regarding the termination of a license agreement is ongoing in New York Supreme Court.
- Investor Lawsuit: Two investors filed a lawsuit alleging fraud and negligent misrepresentation regarding a 2021 private offering. The company filed a motion to dismiss in April 2025.
- Regulatory Risks: Management highlights risks related to potential FDA staffing reductions and budget cuts that could delay product approvals.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for "mid-2025" liquidity exhaustion and the status of any new financing discussions.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by August 4, 2025, to avoid delisting.
- Legal Exposure: Review the progress of the Elion Oncology and investor fraud lawsuits for potential financial liabilities or injunctions.
- Clinical Progress: Confirm enrollment rates and preliminary safety-efficacy data for the NGC-Cap Phase 2 breast cancer trial.
- Dilution: Assess the impact of outstanding warrants (Series A, Series B, and Pre-Funded) on future share count and ownership dilution.